Trial Profile
A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Chloroquine (Primary) ; Darunavir/ritonavir (Primary) ; Favipiravir (Primary) ; Hydroxychloroquine (Primary) ; Lopinavir (Primary) ; Lopinavir/ritonavir (Primary) ; Oseltamivir (Primary) ; Ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms FIGHT-COVID-19
- 28 Aug 2021 Status changed from recruiting to completed.
- 19 Aug 2020 Planned End Date changed from 30 Mar 2021 to 31 Dec 2021.
- 19 Aug 2020 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.